All In Biotech

Drug Trial Radar · NCT07865130

Study of CDK8 Inhibitor RVU120 in Combination With Everolimus in Children With Recurrent or Progressive Group 3 or 4 Medulloblastoma

Phase I Study of CDK8 Inhibitor RVU120 in Combination With Everolimus in Children With Recurrent or Progressive Group 3 or 4 Medulloblastoma

Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

48

Planned (sponsor's estimate)

Start

Sep 2026

Primary completion

Jun 2033

Study completion Jun 2033

Sponsor

Lead sponsor
Bożenna Dembowska BagińskaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Ryvu Therapeutics SA
First posted
Oct 8, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 3 years, up to 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will determine the safety and tolerability of RVU120 as a single agent and in combination with the mTOR inhibitor everolimus in children with recurrent or progressive G3 or G4 medulloblastoma and provide preliminary data regarding the efficacy of this treatment approach.

Conditions

  • Medulloblastoma Recurrent
  • Medulloblastoma

Interventions

  • RVU120Drug

    Experimantal - RVU120

  • Everolimus (Afinitor) tabletsDrug

    RVU120 + everolimus

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency and nature of AEs, SAEs and DLTs according to CTCAE v5.0 in RVU120 monotherapy and combination therapy with everolimusTime frame: From Day1 to 30 days after last dose
  2. MTD and/or RP2D of RVU120 as a single agent and in combination with everolimusTime frame: During Cycle 1 (DLT evaluation period; each cycle is 28 days)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Instytut "Pomnik - Centrum Zdrowia Dziecka", Centrum Wsparcia Pediatrycznych Badań Klinicznych

    Warsaw, Masovian Voivodeship, Poland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.